Physician profile

Ryan Antonawich

Sports Medicine (Family Medicine) · Omaha, NE

NPI 1194454868

$690.67

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$678.57

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Corium, LLC $142.88 2024 Azstarys
Astrazeneca Pharmaceuticals LP $116.77 2023-2024 Farxiga
Novo Nordisk INC $110.61 2024 Wegovy
Amgen INC. $105.90 2023 Repatha
Lilly USA, LLC $84.73 2024 Mounjaro
Abbvie INC. $82.30 2023 Mavyret
Pfizer INC. $17.77 2023
Exact Sciences Corporation $17.61 2023 Cologuard Collection Kit
Organon LLC $12.10 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ryan Antonawich

$690.67

in general payments reported 2019-2025

Years
2022-2024
Top company
Corium, LLC

https://glasscript.com/doctor/11550345/ryan-antonawich

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.